As part of this collaboration, GALT will support four research projects that will use the company's Prospector high-throughput microbial isolation and cultivation system to generate banks of live microbial isolates.
The isolates will be used in studies to develop a more detailed understanding in critical areas of microbiome research: how the microbiome causes different individuals to digest food differently, the microbial basis of disease in a major food crop, how to improve our ability to cultivate microbes from soil, and how the soil microbiome interacts with crop plants and influences crop productivity.
The GALT Prospector system is an array-based platform for microbiome research and product development that enables scientists to cultivate target microbes from complex samples using a massively scalable, easy-to-use workflow.
The system improves the capability and capacity of microbiome research laboratories to screen, isolate and analyze difficult-to-culture or less abundant microbes from complex microbiome samples.
The Penn State Microbiome Center supports transformative, interdisciplinary research in microbiomes by fostering long-term working relationships while simultaneously providing infrastructure and resources needed for increasing the diversity and breadth of microbiome research and educational opportunities at Penn State.
Units involved in the center include the colleges of Agricultural Sciences, Communications, Earth and Mineral Sciences, Engineering, Health and Human Development, Information Sciences and Technology, and Medicine, and the Eberly College of Science.
Also participating are the Huck Institutes of the Life Sciences, the Social Science Research Institute, the Institutes of Energy and the Environment, and the Institute for Computational and Data Sciences.
Active members also come from the Arts Design Research Incubator and from other Penn State campuses.
GALT, a privately held company based in Silicon Valley, is a developer of cultivation and screening platforms for microbiome research and microbial product development, addressing high-impact markets including human health, agriculture, environmental science, and microbial products for industrial use.
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
GSK's meningitis vaccine candidate accepted for FDA review
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
AbbVie announces interim evaluation of Atogepant Phase three, open-label 156-week extension study